Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 1c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.26), $0.01 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $163 thousand versus the consensus estimate of $58.75 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Trump Bought At Least $100,001 In Palantir Shares, Disclosure Shows - Bloomberg
• Wolfe Research Upgrades FOX Corp. (FOXA) to Outperform
• Invitation Homes prices $500 million senior notes offering at 4.950%